Evidence map›Paper›PMID 41357242›Full record

ArticleFrontiers in immunology2025

Significance of SUMOylation in breast cancer progression: a comprehensive investigation using single-cell analysis and bioinformatics.

Wenxing He, Zhengkui Sun, Dongmei Li, Tenghua Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenxing HeBreast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.
Zhengkui SunBreast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.
Dongmei LiJiangxi Key Laboratory of Translational Research for Cancer, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.
Tenghua YuBreast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer remains a major global health challenge because of limitations in early detection and therapeutic outcomes. This study employed bulk and single-cell RNA sequencing to investigate SUMOylation-associated molecular networks, aiming to identify prognostic biomarkers and potential therapeutic applications. Methods: Transcriptomic profiling was performed on 1,445 breast cancer and 113 normal samples to identify differentially expressed genes. Four hub genes, Results: Tumor tissues exhibited significant upregulation of Conclusion: Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticSumoylationAnimalsAurora Kinase ABiomarkers, TumorCase-Control StudiesCell Cycle ProteinsDatasets as TopicDisease ProgressionFemaleHumansMolecular Targeted TherapyPolo-Like Kinase 1Receptors, MineralocorticoidSingle-Cell Gene Expression AnalysisAURKA protein, humanAurora Kinase ABiomarkers, TumorCDCA8 protein, humanCell Cycle ProteinsNR3C2 protein, humanPLK1 protein, humanPolo-Like Kinase 1Receptors, MineralocorticoidTranscription Factorsbiomarkersbreast cancerimmune infiltrationscRNASUMOylation

Identifiers

PMID41357242
PMCPMC12676025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.